The validations confirm the completion of the applications and commence the scientific review process
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
ANVISA issues CGMP to Concord Biotech’s Unit I
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
The product will be launched in March 2024
Cipla completes transfer of Generics Business Undertaking
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Subscribe To Our Newsletter & Stay Updated
